Ian Dixon, CEO of Genscreen Pty Ltd, announces that Genscreen is presently having TR400 drugs sythesised by a contractor. It is anticipated that screening results will be ready for review by March 2010.
TR400 is the development lead series of Trobio Pty Ltd, a subsidiary of Genscreen Pty Ltd.
Two other development series are also under development for complementary applications - TR500 and TR600.
The intention is to outlicense TR400 as soon as a suitable partner can be found.
Genscreen Pty Ltd is a privately-held company with a portfolio of 5 projects across therapeutic applications that include cancer, MS and other diseases caused by viral infections.
January 2010
January 15th, 2010 · No Comments
Tags: news
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
Leave a Comment